SEC v. SPENCER PHARMACEUTICAL INC, No. 1:12-cv-12334 (Dec. 17, 2012)
raw: suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange
suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange, No. 1:12-cv-12334 (Dec. 17, 2012)
The SEC temporarily suspended trading in Spencer Pharmaceutical Inc. (SPPH) from December 17–31, 2012, due to concerns over misleading press releases about a foreign buyout offer and inaccurate financial disclosures, with no formal charges filed but strict compliance requirements imposed before trading could resume.
The Securities and Exchange Commission suspended trading in Spencer Pharmaceutical Inc. (SPPH) from December 17 to December 31, 2012, citing concerns about the accuracy and adequacy of its public disclosures, including false or misleading statements regarding a purported foreign buyout offer and the company’s financial condition. No specific individuals were charged, and no financial penalties were imposed at this stage—the action was a precautionary trading halt to protect investors. The SEC mandated strict compliance with Rule 15c2-11 before any future quotations could be entered and acknowledged assistance from Quebec’s Autorité des Marchés Financiers in the investigation.
The Securities and Exchange Commission temporarily suspended trading in Spencer Pharmaceutical Inc. (SPPH) from December 17 to December 31, 2012, due to serious concerns about the accuracy and adequacy of publicly disseminated information, particularly misleading press releases concerning a purported unsolicited buyout offer by a foreign company and the company’s true financial condition. No formal fraud charges or financial penalties were announced, as the action was a precautionary trading halt designed to prevent investor harm while the SEC assessed the validity of the disclosures. The Commission emphasized that no broker or dealer could resume quoting SPPH securities without strictly complying with Rule 15c2-11, warning that violations would trigger prompt enforcement action. The SEC acknowledged the assistance of Quebec’s Autorité des Marchés Financiers, indicating cross-border regulatory cooperation in uncovering potential misconduct. Investors, brokers, and prospective purchasers were explicitly cautioned to rely only on verified, current information and to avoid acting on unconfirmed claims. The suspension underscored the SEC’s focus on ensuring transparency and due diligence in over-the-counter markets, particularly when material misrepresentations may be influencing market behavior. No dollar amounts or specific financial figures were disclosed in the notice, and the outcome remained limited to the temporary halt and compliance directives without further adjudication at that time.
Extracted insights
- person john t. dugan
- agency Securities and Exchange Commission
- organization Securities and Exchange Commission
- Securities and Exchange Commission temporarily suspended trading securities of Spencer Pharmaceutical Inc. (SPPH) due to concerns about accuracy of financial disclosures and press releases regarding a foreign buyout offer
- Securities and Exchange Commission cautioned brokers, dealers, shareholders, and prospective purchasers to consider all available information before trading Spencer's securities
- Securities and Exchange Commission enforced Rule 15c2-11 to prohibit quotations in Spencer's securities after suspension unless all rule provisions are strictly complied with
- Securities and Exchange Commission acknowledged assistance from Quebec Autorité des Marchés Financiers in connection with the trading suspension
- John T. Dugan should be contacted by brokers, dealers, or persons with information relating to Spencer's trading suspension at (617) 573-8900
UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release No. 68447 / December 17, 2012 The Securities and Exchange Commission (“Commission”) announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities of S pencer Pharmaceutical Inc. (“Spencer”), commencing at 9:30 a.m. EST on Monday, December 17, 2012, through 11:59 p.m. EST on Monday, December 31, 2012. The Commission temporarily suspended trading in the securities of Spencer because of questions regarding the accuracy and adequacy of publicly disseminated information concerning, among other things, the company’s current financial condition and statements made by Spencer in press releases concerning, among other things, an unsolicited buyout offer of Spencer by a foreign company. Spencer’s ticker symbol is SPPH. The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company. Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to Spencer’s securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action. The Commission acknowledges the assistance of the Quebec Autorité des Marchés Financiers in connection with this matter. If any broker, dealer, or other person has any information which may relate to this matter, John T. Dugan of the Boston Regional Office of the Securities and Exchange Commission should be telephoned at (617) 573-8900.
UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release No. 68447 / December 17, 2012 The Securities and Exchange Commission (“Commission”) announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities of Spencer Pharmaceutical Inc. (“Spencer”), commencing at 9:30 a.m. EST on Monday, December 17, 2012, through 11:59 p.m. EST on Monday, December 31, 2012. The Commission temporarily suspended trading in the securities of Spencer because of questions regarding the accuracy and adequacy of publicly disseminated information concerning, among other things, the company’s current financial condition and statements made by Spencer in press releases concerning, among other things, an unsolicited buyout offer of Spencer by a foreign company. Spencer’s ticker symbol is SPPH. The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company. Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to Spencer’s securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action. The Commission acknowledges the assistance of the Quebec Autorité des Marchés Financiers in connection with this matter. If any broker, dealer, or other person has any information which may relate to this matter, John T. Dugan of the Boston Regional Office of the Securities and Exchange Commission should be telephoned at (617) 573-8900.